![Douglas Kling](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 223 017 $ al 31/08/2026
Douglas F.
Kling is Chief Operating Officer at NewAmsterdam Pharma BV and NewAmsterdam Pharma Holding BV since 2021.
Former positions include Chief Operating Officer at NewAmsterdam Pharma Co. NV from 2021 to 2026, Senior Vice President-Clinical Operations at Corvidia Therapeutics, Inc. from 2017 to 2021, SVP-Clinical Development & Project Management at Matinas BioPharma Holdings, Inc. from 2015 to 2017, Senior Vice President-Clinical Development at Omthera Pharmaceuticals, Inc. from 2010 to 2014, Senior Director-Project Management at Shionogi USA Holdings, Inc. from 2009 to 2010, Senior Director-Program Management at The Medicines Co. from 2008 to 2009, Director-R&D Project Management at Reliant Pharmaceuticals LLC from 2000 to 2008, and Manager-Clinical Research at Knoll Pharmaceutical Co. from 1998 to 2000.
Education includes undergraduate studies at Duke University and an MBA from Rutgers Business School.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 15/04/2026 | 8.801 ( 0,01 % ) | 223 017 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Engages in research and development of transformative therapies for cardio metabolic diseases | Director de Operaciones | 01/03/2021 |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat dyslipidemia | Director de Operaciones | 01/03/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Director de Operaciones | 14/08/2026 |
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Develops precision cardiovascular therapies | Corporate Officer/Principal | 01/02/2021 |
| MATINAS BIOPHARMA HOLDINGS, INC. | Corporate Officer/Principal | 01/11/2017 |
Omthera Pharmaceuticals, Inc.
 Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia | Corporate Officer/Principal | 01/12/2014 |
Shionogi USA Holdings, Inc. | Corporate Officer/Principal | 01/07/2010 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 12 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
Reliant Pharmaceuticals LLC
 Reliant Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia | Health Technology |
Matinas BioPharma Holdings, Inc.
 Matinas BioPharma Holdings, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Knoll Pharmaceutical Co. | |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat dyslipidemia | Health Technology |
Rutgers Business School
 Rutgers Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shionogi USA Holdings, Inc. | |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Develops precision cardiovascular therapies | Health Technology |
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Engages in research and development of transformative therapies for cardio metabolic diseases | Health Technology |
NewAmsterdam Pharma Co. NV
 NewAmsterdam Pharma Co. NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops, manufactures and commercializes transformative therapies for cardio-metabolic diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
